HOLX logo

Hologic Stock Price

Symbol: NasdaqGS:HOLXMarket Cap: US$15.1bCategory: Healthcare

HOLX Share Price Performance

US$67.82
-14.63 (-17.74%)
3.0% undervalued intrinsic discount
US$69.93
Fair Value
US$67.82
-14.63 (-17.74%)
3.0% undervalued intrinsic discount
US$69.93
Fair Value
Price US$67.82
AnalystConsensusTarget US$69.93

HOLX Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value US$69.93 3.0% undervalued intrinsic discount

Breast Health Sales And Diagnostics Will Create Future Opportunities

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative

HOLX Community Fair Values

Recent HOLX News & Updates

No updates

Hologic, Inc. Key Details

US$4.0b

Revenue

US$1.6b

Cost of Revenue

US$2.5b

Gross Profit

US$1.9b

Other Expenses

US$557.1m

Earnings

Last Reported Earnings
Jun 28, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
2.50
Gross Margin
60.86%
Net Profit Margin
13.79%
Debt/Equity Ratio
51.8%

Hologic, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About HOLX

Founded
1985
Employees
7063
CEO
Stephen MacMillan
WebsiteView website
www.hologic.com

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

U.S. Market Performance

  • 7 Days: -1.2%
  • 3 Months: 13.1%
  • 1 Year: 22.8%
  • Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a pullback of 4.7% in the Consumer Discretionary sector. As for the longer term, the market has actually risen by 23% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading